share_log

As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M

As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M

作爲Wave Life Sciences與葛蘭素史克持續合作的一部分，葛蘭素史克已經選擇了其前兩個寡核苷酸項目，葛蘭素史克將提供1200萬美元的啓動金
Benzinga ·  04/23 22:22
  • GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNAc-siRNA format with potential for best-in-class potency and durability
  • GSK collaboration continues to span all Wave modalities, including RNA editing, with target validation ongoing in multiple therapy areas
  • Wave is on track to initiate a clinical trial of its wholly owned INHBE program for obesity in 1Q 2025, which also uses the company's next generation siRNA
  • 葛蘭素史克選擇了在實現目標驗證後推進的前兩個項目，這標誌着研究合作已過渡到下一階段；項目採用了Wave的下一代Galnac-siRNA格式，有可能實現同類最佳的效力和耐久性
  • 葛蘭素史克的合作繼續涵蓋所有Wave模式，包括RNA編輯，多個治療領域的靶標驗證正在進行中
  • Wave有望在2025年第一季度啓動其全資的INHBE肥胖項目臨床試驗，該項目還使用該公司的下一代siRNA

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論